JAGUAR HEALTH INC (JAGX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$1.62-20.59%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put JAGX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce EPS loss from -$4.20 in 2026 to less negative levels: Comparison needs review.
View ThesisManagement screens weak on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementThis stock is highly volatile — it swings about 6% on a typical day and fell roughly 100% in its worst 12-month stretch.
View RiskJAGX rests on developing crofelemer powder for rare intestinal failure, despite recent performance being strong. The latest quarter beat, but revenue fell 59% year over year. No valuation bridge or peer multiple is provided, so the price’s growth expectations remain unverified. The risk is fragile earnings quality, with reported profits not well backed by cash. Our model puts the next-quarter miss probability near 50%. The thesis is on watch; the comparison needs review, not confirmation of a broken pillar. This read is provisional.
Trailing returns as of 2026-10-30. JAGX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering JAGX (as of May 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare JAGX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JAGX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put JAGX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Develop and commercialize crofelemer powder for rare intestinal failure
Pipeline news boosts confidence in crofelemer development.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Maintain Nasdaq listing compliance
Reverse split may affect Nasdaq listing compliance.
Advances: Develop and commercialize crofelemer powder for rare intestinal failure
MVID drug application supports product development objective.
Advances: Develop and commercialize crofelemer powder for rare intestinal failure
Earnings call highlights breakthroughs in rare disease treatments.
Advances: Develop and commercialize crofelemer powder for rare intestinal failure
NDA filing timeline enhances product commercialization prospects.
